NCT03884179

Brief Summary

Pancreatic cystic lesions (PCLs) comprise of a heterogeneous group of entities that are benign, premalignant or malignant. With increased use of modern imaging techniques in recent years, incidentally discovered PCL have become much more common. However, imaging modalities for characterising PCL is a known clinical uncertainty since imaging is capable of detecting these lesions but may often not be able to distinguish malignant from benign lesions. Incorrect assessment of PCL can lead to fatal consequences because a malignant lesion may not be treated and a benign may be unnecessarily resected. The aim of this study was to assess the performance of endoscopic ultrasound with fine-needle aspiration (EUS-FNA) in the diagnosis of pancreatic cystic lesions compared to cross-sectional imaging modalities (CT/MRI). Our hypothesis is that EUS-FNA has a higher accuracy for diagnosing PCLs compared with cross-sectional imaging.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
58

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Feb 2007

Longer than P75 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2007

Completed
10.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

April 24, 2018

Completed
11 months until next milestone

First Posted

Study publicly available on registry

March 21, 2019

Completed
12 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2020

Completed
Last Updated

March 21, 2019

Status Verified

March 1, 2019

Enrollment Period

10.8 years

First QC Date

April 24, 2018

Last Update Submit

March 19, 2019

Conditions

Keywords

Endoscopic ultrasoundRadiologyAccuracyPancreatic CystPancreatic CystadenocarcinomaPancreatic Mucinous CystadenomaPancreatic Intraductal Papillary-Mucinous NeoplasmPancreatic Serous CystadenomaPancreatic PseudocystPancreatic Neuroendocrine TumorSolid Pseudopapillary Tumor of the Pancreas

Outcome Measures

Primary Outcomes (1)

  • Accuracy of EUS-FNA vs Radiology

    To compare the accuracy of EUS-FNA(morphology, cytology, CEA(ng/ml)) with CT/MRI in the diagnosis of pancreatic cystic lesions. Surgical pathology is used as gold standard Established CEA cut-offs of \>192 ng/ml were used for mucinous assessment and \>1000 ng/ml for established cancer assessment. A CEA value of 5 ng/ml or less was indicative of a serous cyst

    10 years

Secondary Outcomes (3)

  • Accuracy of EUS-FNA vs morphology

    10 years

  • Accuracy of EUS FNA vs cytology

    10 years

  • Accuracy of EUS FNA vs CEA

    10 years

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All patients with suspected PCLs according to radiology undergoing evaluation with EUS-FNA at a tertiarry endoscopy center from February 2007 until March 2017. The catchemnt area of this cente has a population of about two million.

You may qualify if:

  • Patients with suspected PCLs according to radiology undergoing evaluation with EUS-FNA at a tertiarry endoscopy center from February 2007 until March 2017, who underwent pancreas resection
  • Oral and written consent of patients examined

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Pancreatic CystSomatostatinomaPancreatic PseudocystPancreatic Intraductal NeoplasmsAdenoma, Islet Cell

Condition Hierarchy (Ancestors)

CystsNeoplasmsPancreatic DiseasesDigestive System DiseasesCarcinoma, NeuroendocrineNeuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialCarcinoma, Islet CellPancreatic NeoplasmsDigestive System NeoplasmsNeoplasms by SiteEndocrine Gland NeoplasmsEndocrine System DiseasesNeoplasms, Ductal, Lobular, and MedullaryAdenoma

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Ass Prof

Study Record Dates

First Submitted

April 24, 2018

First Posted

March 21, 2019

Study Start

February 1, 2007

Primary Completion

December 1, 2017

Study Completion

March 1, 2020

Last Updated

March 21, 2019

Record last verified: 2019-03